To explore this experimentally, we used doxycycline‐inducible shRNA‐mediated knockdown of ADAR1 in a human oral squamous cell carcinoma cell line (CAL27), which was previously shown to be sensitive to ADAR1 loss (Liu et al, 2019) and that upregulates LGP2 upon type I IFN treatment (Fig EV5A). Here, ADAR is linked to oral cavity squamous cell carcinoma.